TY  - JOUR
T1  - FIngolimod precautions
AU  - Kuehn BM
Y1  - 2012/06/27
N1  - 10.1001/jama.2012.7064
JO  - JAMA
SP  - 2578
EP  - 2578
VL  - 307
IS  - 24
N2  - 
Based on analysis of the sudden unexplained death of 1 patient and reports of cardiovascular adverse events, including some deaths in other patients, the FDA concluded it could not determine whether fingolimod caused these events (http://tinyurl.com/d2zazcd). However, the agency expressed its concern about the cardiovascular effects of the drug, particularly the first dose. According to the FDA, the drug may lower the heart rate, with the greatest effect occurring during the first 6 to 20 hours of first use.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.7064
UR  - http://dx.doi.org/10.1001/jama.2012.7064
ER  -